Price movement over the last 24 hours
Global X MSCI Argentina ETF vs Regeneron Pharmaceuticals Inc — how do they compare? Global X MSCI Argentina ETF trades at $95.07, while Regeneron Pharmaceuticals Inc trades at $664.52 (market cap $69.67B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Global X MSCI Argentina ETF pays none, and Global X MSCI Argentina ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ARGT | REGN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $102.94 | $812.27 |
52-Week Low | $67.55 | $542.52 |
Market Cap | — | $69.67B |
Enterprise Value | — | $63.62B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.
The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.
Regeneron (REGN) trades at $664.52, down 0.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong fundamentals with a P/E of 16.22, net income margin of 29.65%, and consistent earnings beats. Recent FDA acceptance for cemdisiran review and inclusion in a manufacturing facility pilot program highlight positive developments. Cash flow improved in 2025 with net cash flow of $634.70 million.
Outlook remains positive with a consensus price target of $764.50, implying 15% upside, supported by 69% analyst buy ratings. Risks include regulatory hurdles, competitive pressures, and dependence on key drug performance. The stock presents a compelling opportunity for growth investors given its valuation and pipeline progress, though near-term volatility may persist around earnings.
Trailing returns across standard periods
ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.
Read more on ARGT →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →